Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06045793
Other study ID # TNX-CE-CI202
Secondary ID 5U01DA056245
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date December 11, 2023
Est. completion date June 4, 2024

Study information

Verified date November 2023
Source Tonix Pharmaceuticals, Inc.
Contact Sr. Manager, Clinical Programs
Phone 203-482-3938
Email Megha.Tevar@tonixpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date June 4, 2024
Est. primary completion date June 4, 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Subject is male (sex assigned at birth). - Subject is 18-64 years of age. - Subject has the capacity to provide voluntary written informed consent. In cases in which the investigator is unclear if the subject has the capacity to consent, a determination regarding capacity must be made by a psychiatrist trained in assessment of capacity to consent to research in order for the subject to be eligible. - At Screening, subject presents with cardiac symptoms while intoxicated with cocaine, inclusive of elevated systolic and diastolic BP, as defined below, with or without behavioral symptoms: - Systolic BP >140 mmHg - Diastolic BP >90 mmHg Note: subjects with a QT interval corrected for heart rate (QTc) >500 msec may be eligible for study participation, based on investigator judgment. - At Screening and Baseline assessments, subject must have a SIS total score of =4 and a score >1 on at least one of the 2 BP items (systolic and diastolic BP). - At Baseline, subject has a CGI-S score =3. - Subject has a positive urine drug screen test at Pre-screening to confirm cocaine use and detect polysubstance abuse (subject may test positive for cannabinoids and/or opioids and remain eligible; subject may test positive for alcohol by breathalyzer and remain eligible). - Subject is a suitable candidate for investigational treatment based on the opinion of the investigator. Exclusion Criteria: - Subject who has been admitted to the ED involuntarily. - Subject who participated in this clinical study previously. - Subject has a score of 3 on the systolic and/or diastolic BP SIS components, a "mental state" or "orientation" SIS component score of =2, or an "orientation" SIS component score of =1 and the subject is not oriented to either person or place. - Subject who, at Screening, expresses C-SSRS suicidal ideation of Type 4 or 5 in the prior week or any C-SSRS suicidal behavior in the prior week. - Subject tests positive for stimulant drugs of abuse other than cocaine, including methylphenidate, 3,4-methylenedioxymethamphetamine, methamphetamine, or other amphetamines at Screening. - Subject has a clinically significant untreated cardiac condition, such as prior myocardial infarction, current ischemia or severe left ventricular hypertrophy assessed by ECG-based criteria, aortic dissection, ventricular fibrillation, Torsade de pointes, ventricular tachycardia, cardiomyopathy, pulmonary edema, cardiac arrest, significant conduction disturbance (e.g., greater than first degree heart block), QRS interval >120 msec, or severe or life-threatening hypertension. Untreated hypertension may be allowed if not considered severe or life-threatening. Note: hypertension will be considered severe or life-threatening if systolic BP is >200 mmHg and/or diastolic BP is >130 mmHg. - Subject incurred or is likely to incur a myocardial infarction or other life-threatening severe event or has acute ECG changes indicative of acute coronary syndrome according to investigator judgment. Such changes may include new, transient, or dynamic ST-segment elevation, ST-depression, or significant Q waves. Based on investigator judgement, T-wave inversion and T-wave flattening may also be considered in the risk assessment for acute coronary syndrome. - Subject has a heart rate =180 bpm, atrial fibrillation, greater than first degree heart block, or chest pain with ECG-based evidence of ischemia. - Subject has a clinically significant or unstable medical illness, condition, or disorder that can compromise subject safety or adversely affect the evaluation of clinical outcome parameters. - Subject has a clinical history of anaphylaxis, severe asthma, hypersensitivity, or angioedema. - Subject requires physical restraints due to physiological and/or behavioral symptoms. - Subject receives anti-hypertensive medication(s) in the ED prior to study enrollment. - Participation in another investigational drug study (current or within 30 days of Screening) or previous participation in a study of TNX-1300.

Study Design


Intervention

Drug:
TNX-1300 (Injection)
Patients will receive a single IV injection of TNX-1300.
Placebo (Injection)
Patients will receive a single IV injection of placebo with usual care (UC).

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Tonix Pharmaceuticals, Inc. National Institute on Drug Abuse (NIDA), Premier

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Systolic BP at 60 minutes after dosing, comparing TNX-1300 to placebo with UC Patients will undergo a Systolic BP assessment at Baseline and at 60 minutes after dosing. 60 minutes after IV administration
Secondary Change from Baseline in QT interval corrected for heart rate (QTc) at 15 minutes after dosing, comparing TNX-1300 to placebo with UC Patients will undergo a 12-lead ECG at Baseline and at 15 minutes after dosing. 15 minutes after IV administration
Secondary Change from Baseline in diastolic BP at 60 minutes after dosing, comparing TNX-1300 to placebo with UC Patients will undergo a Diastolic BP assessment at Baseline and at 60 minutes after dosing 60 minutes after IV administration
Secondary Change from Baseline in Stimulant Intoxication Scale (SIS) total score at 60 minutes after dosing, comparing TNX-1300 to placebo with UC Patients will be assessed with the SIS for characterizing severity of cocaine intoxication at Baseline and at 60 minutes after dosing. The SIS has 6 items, each of which is scored on a range of 0-3 (4 items) or 0-4 (2 items). The SIS has a total score range of 0 to 20, with 0 being the lowest severity and 20 being the highest severity. 60 minutes after IV administration
See also
  Status Clinical Trial Phase
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Completed NCT00842517 - Long Term Maintenance of Drug Abstinence Phase 1
Completed NCT00227903 - Therapeutic Substance Abuse Treatment in Pregnancy - 1 Phase 2
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT02563769 - Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study Phase 1
Completed NCT01651377 - Pramipexole as a Treatment for Cocaine Dependence Phase 1
Recruiting NCT00439049 - Substance Abuse Pre-Treatment Screening Study
Completed NCT00249457 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2 N/A
Completed NCT01401270 - Prize Contingency Management for Cocaine-Dependent Methadone Patients N/A
Completed NCT00350610 - Computer-Based Training in Cognitive Behavior Therapy Phase 1
Recruiting NCT06177860 - Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
Completed NCT02393599 - Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin Phase 1
Completed NCT02141620 - n-Acetylcysteine and Cocaine Phase 0
Recruiting NCT00218023 - Medications for Stopping Cocaine Dependence and Preventing Relapse Phase 2
Completed NCT00218075 - Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence Phase 2
Recruiting NCT05857852 - Low-Intensity Focused Ultrasound for Cocaine Use Disorder N/A
Completed NCT00606801 - Galantamine Effects on Cognitive Function in Abstinent Cocaine Users N/A
Completed NCT00292123 - Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse Phase 1
Completed NCT00318760 - Effect of Clonidine on Responses to Imagery Scripts Phase 1